FindTrial
Sign In

Sildenafil and milrinone help in reducing Lung pressure in babies

Efficacy of Milrinone and Sildenafil in the management of Persistent Pulmonary Hypertension in Neonates in Resource Limited Setting- Open label Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/104791
Enrollment
40
Registered
2026-02-25
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I288- Other diseases of pulmonary vessels

Interventions

Intervention1: Inj Milrinone and Inj Sildenafil: Inj Milrinone 50 mcg/kg IV loading dose over 1 hour followed by 0.5 mcg/kg/min (0.33-0.75 mcg/kg/min) AND Inj Sildenafil 0.4 mg/kg IV loading over 3

Sponsors

Govt Medical college
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All term neonates (less than 10 days old) with PPHN diagnosed by Clinical and echocardiography indicated for treatment

Exclusion criteria

Exclusion criteria: Major congenital anomalies ,Congenital heart disease,Congenital Diaphragmatic hernia,Imminent Death in 24 hrs,Parents who refuse to give consent

Design outcomes

Primary

MeasureTime frame
1.Reduction of PASP after 24 hrs 2.Reduction in OSI Timepoint: 24 hours of life—

Secondary

MeasureTime frame
1.Effect on Mortality 2.Ventilation days 3.Maximum ventilator settings 4.Hospital stay Timepoint: Till discharge—

Countries

India

Contacts

Public ContactAtul Chandrakant Londhe

Government Medical College and Hospital Aurangabad

atul.londhe1982@gmail.com8275453997

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026